Form 4 for CYH COMMUNITY HEALTH SYSTEMS INC
Accepted 2023-03-02 00:00:00 ET · period of report 2023-03-01 · accession 0001209191-23-014698 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2023-03-02 | 2023-03-01 | CYH | Pitt Justin D | EVP, GC | F - Tax | $6.15 | -1,484 | 19.1K | -7% | -$9,127 |
| D | 2023-03-02 | 2023-03-01 | CYH | Pitt Justin D | EVP, GC | F - Tax | $6.15 | -15.3K | 174.6K | -8% | -$94.2K |
| D | 2023-03-02 | 2023-03-01 | CYH | Pitt Justin D | EVP, GC | A - Grant | $0.00 | +30.0K | 189.9K | +19% | $0 |
| D | 2023-03-02 | 2023-03-01 | CYH | Pitt Justin D | EVP, GC | M - OptEx | $0.00 | +20.0K | 159.9K | +14% | $0 |
| DI | 2023-03-02 | 2023-03-01 | CYH | Pitt Justin D | EVP, GC | A - Grant | $0.00 | +5,000 | 20.6K | +32% | $0 |
| DM | 2023-03-02 | 2023-03-01 | CYH | Pitt Justin D | EVP, GC | A - Grant | $0.00 | +60.0K | 30.0K | New | $0 |
| D | 2023-03-02 | 2023-03-01 | CYH | Pitt Justin D | EVP, GC | M - OptEx | $0.00 | -20.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-01 | F | D | 1,484 | $6.15 | 19,069 | I | — | — | |
| 2 | Common | Common Stock | 2023-03-01 | F | D | 15,319 | $6.15 | 174,613 | D | — | — | |
| 3 | Common | Common Stock | 2023-03-01 | A | A | 30,000 | $0.00 | 189,932 | D By spouse | — | — | (F2) The time-vesting restrictions on this award of restricted stock will lapse in 1/3 increments on the first, second and third anniversary of the date of grant. (F3) The Reporting Person's spouse is employed by an affiliate of the Issuer. |
| 4 | Common | Common Stock | 2023-03-01 | M | A | 20,000 | $0.00 | 159,932 | D By spouse | — | — | (F1) The vesting of these performance-based restricted shares was based on the attainment of certain performance objectives between 1/1/2020 and 12/31/2022 (the "2020-2022 Performance Period"). Based on the actual level of achievement of such performance objectives for the 2020-2022 Performance Period, the award vested on March 1, 2023 at 100% of the target number of the performance-based restricted shares originally reported by the Reporting Person on 3/2/2020. (F3) The Reporting Person's spouse is employed by an affiliate of the Issuer. |
| 5 | Common | Common Stock | 2023-03-01 | A | A | 5,000 | $0.00 | 20,553 | I | — | — | (F2) The time-vesting restrictions on this award of restricted stock will lapse in 1/3 increments on the first, second and third anniversary of the date of grant. |
| 6 | Derivative | Stock Options (Right to Buy) | 2023-03-01 | A | A | 30,000 | $0.00 | 30,000 | D | $6.15 · 2024-03-01 to 2033-02-28 | 30,000 Common Stock | (F5) Vesting occurs in 1/3 increments on the first, second and third anniversary of the date of grant. |
| 7 | Derivative | Performance Based Restricted | 2023-03-01 | M | D | 20,000 | $0.00 | 0 | D | $0.00 · — to — | 20,000 Common Stock | (F1) The vesting of these performance-based restricted shares was based on the attainment of certain performance objectives between 1/1/2020 and 12/31/2022 (the "2020-2022 Performance Period"). Based on the actual level of achievement of such performance objectives for the 2020-2022 Performance Period, the award vested on March 1, 2023 at 100% of the target number of the performance-based restricted shares originally reported by the Reporting Person on 3/2/2020. |
| 8 | Derivative | Performance Based Restricted | 2023-03-01 | A | A | 30,000 | $0.00 | 30,000 | D | $0.00 · — to — | 30,000 Common Stock | (F4) The vesting of these performance-based restricted shares is allocated to the attainment of the following pre-determined performance objectives between 1/1/2023 and 12/31/2025 (the "2023-2025 Performance Period"), as follows: 50% to a Cumulative Consolidated Adjusted EBITDA Growth target; and 50% to a Cumulative Same-Store Net Revenue Growth target. The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2023-2025 Performance Period. |